CD19 and acute lymphoblastic leukemia: Collectively, the data fully support the initiation of a first-in-human Phase 1 clinical trial to examine the safety of BAFF-R CAR T cells, particularly given the urgent need to address r/r B-ALL following CD19-targeted immunotherapy.